Phase 1 Safety and PK Study of OLT1177 Capsules
A Phase 1, Randomized, Dose Escalation, Single Center, Safety and Pharmacokinetic Study of Single and Multi-Dose, Orally Administered OLT1177 Capsules in Healthy Subjects
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Texas
-
College Station, Texas, Estados Unidos, 77845
- J&S Studies, Inc
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age 18 to 60 years old, inclusive
- In good health as determined by the Investigator based on subject's medical history, ECG and physical examination at Baseline and safety laboratory tests (chemistry, hematology, coagulation and urinalysis) at Screening
- Normal blood pressure of 130/85 mmHg or lower
- Ability to provide written, informed consent prior to initiation of any study-related procedures, and ability, in the opinion of the Investigator, to comply with all the requirements of the study
Exclusion Criteria:
Women of childbearing potential, or men whose sexual partner(s) is a woman of childbearing potential who:
- Are or intend to become pregnant (including use of fertility drugs) during the study
- Are nursing
- Are not using an acceptable, highly effective method of contraception until all follow-up procedures are complete. (Acceptable, highly effective forms of contraception are defined as: oral contraception, intrauterine device, systemic [injectable or patch] contraception, double barrier methods, naturally or surgically sterile, strict abstinence or partner has been sterilized. If hormonal-based birth control is being used, subject or subject's sexual partner(s) must be on a stable-dose for ≥ 3 months prior to the Baseline visit and maintained at the same dosing level throughout the study.)
- Use of any drug treatment at the time of the study (with the exception of 81 mg aspirin and prescription oral or systemic contraceptives)
- Taking any prescription medications (other than oral or systemic contraceptives) within 14 days prior to administration of investigational drug or taking any over-the-counter products (including natural food supplements, vitamins, garlic as a supplement) within 14 days prior to administration of investigational drug, except for topical products without systemic absorption
- Use of NSAIDs or other prescription pain medication, more than once or twice a week, especially if taken for chronic or frequently recurring headache
- Active infection within 3 days of the Baseline visit
- History of or known positive for HIV, Hepatitis B surface antigen (HBsAg) or antibodies to Hepatitis C Virus (HCV)
- Diagnosed with any form of internal cancer within the past 5 years
- Any other medical conditions, diseases or prior surgeries that in the opinion of the Investigator would impair the subject from safely participating in the trial and/or completing any protocol requirements
- History of anaphylactic reactions to any systemic or topical compounds
- Have donated plasma (500 mL) within 7 days prior to drug administration
- Have donated or lost whole blood (excluding the volume of blood that will be drawn during the screening procedures of this study) prior to administration of the study medication as follows: 50 mL to 499 mL of whole blood within 30 days, or more than 499 mL of whole blood within 56 days prior to drug administration
- Is a user of any nicotine products (including chewing tobacco, snuff and/or e-cigarettes)
- Is not willing to restrict food or beverage including: alcohol, caffeine, poppy seeds, xanthine derivatives or xanthine-related compounds, energy drinks, natural health products, grapefruit juice, pomelo, Seville orange and marmalade use during the study as specified in Section 7.1.5
- Is lactose intolerant
- Is unable or unwilling to consume products containing bovine byproducts
- Is unable to adhere to or understand the requirements of the protocol
- If continuing on to Part B, subject is unable or unwilling to ingest the full study-provided high-fat breakfast within 30 minutes
- Enrollment in any trial and/or use of any Investigational Drug or device within the immediate 30-day period prior to the Baseline visit
- Enrollment in any study previously sponsored by Olatec Industries LLC, specifically Study OLT1177-01, Study OLT1177-02 or Study OLT1177-03
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: OLT1177 Capsules
A total of 5 patients in each cohort will receive OLT1177 Capsules:
|
OLT1177 Capsules are an experimental drug.
|
|
Comparador de placebos: Placebo Capsules
A total of 1 patient in each cohort will receive Placebo Capsules:
|
Placebo Capsules are identical in all ways to the study drug, but contain no active pharmaceutical ingredient.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Recording of adverse events
Periodo de tiempo: Screening through Day 28 follow-up
|
Adverse events will be described with respect to seriousness, intensity, relationship to treatment, action taken and outcome of the event.
|
Screening through Day 28 follow-up
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Safety Laboratory Measurements
Periodo de tiempo: Screening through Day 15 (Part A&B)/Day 22 (Part C) visit
|
Blood samples will be drawn and analyzed for: chemistry, hematology, lipids and coagulation.
|
Screening through Day 15 (Part A&B)/Day 22 (Part C) visit
|
|
Electrocardiogram
Periodo de tiempo: Screening through Day 15 (Part A&B)/Day 22 (Part C) visit
|
Electrocardiograms will be captured and analyzed for changes throughout the duration of the study.
|
Screening through Day 15 (Part A&B)/Day 22 (Part C) visit
|
|
Vital Signs
Periodo de tiempo: Screening through Day 15 (Part A&B)/Day 22 (Part C) visit
|
Vital signs (pulse, resting blood pressure, temperature and respirations) will be recorded and analyzed for changes throughout the duration of the study.
|
Screening through Day 15 (Part A&B)/Day 22 (Part C) visit
|
|
Physical Examination
Periodo de tiempo: Screening through Day 15 (Part A&B)/Day 22 (Part C) visit
|
Physical examinations will be conducted to assess changes in subject health throughout the duration of the study.
|
Screening through Day 15 (Part A&B)/Day 22 (Part C) visit
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Terry M Jones, MD, FAAD, J&S Studies
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- OLT1177-04
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .